HROW Quote, Financials, Valuation and Earnings

Regeneron Pharmaceuticals, Inc. has a net margin of 1.42% compared to Harrow, Inc.'s net margin of 21.74%. Harrow, Inc.'s return on equity of -8.95% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Harrow, Inc. has a consensus price target of $70.63, signalling upside risk potential of 30.35%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.3%. Given that Harrow, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Harrow, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Harrow, Inc. has a beta of 0.073, which suggesting that the stock is 92.734% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Harrow, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Harrow, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Harrow, Inc. quarterly revenues are $71.6M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Harrow, Inc.'s net income of $1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Harrow, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow, Inc. is 8.09x versus 5.92x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of 1.42% compared to Harrow, Inc.'s net margin of -360.68%. Harrow, Inc.'s return on equity of -8.95% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Harrow, Inc. has a consensus price target of $70.63, signalling upside risk potential of 30.35%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $41.70 which suggests that it could grow by 14.53%. Given that Harrow, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Harrow, Inc. is more attractive than Stoke Therapeutics, Inc..

Harrow, Inc. has a beta of 0.073, which suggesting that the stock is 92.734% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.101, suggesting its more volatile than the S&P 500 by 10.054%.

Harrow, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Harrow, Inc. quarterly revenues are $71.6M, which are larger than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Harrow, Inc.'s net income of $1M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Harrow, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 55.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow, Inc. is 8.09x versus 10.33x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology, Inc. has a net margin of 1.42% compared to Harrow, Inc.'s net margin of -66.99%. Harrow, Inc.'s return on equity of -8.95% beat Vir Biotechnology, Inc.'s return on equity of -46.56%.

Harrow, Inc. has a consensus price target of $70.63, signalling upside risk potential of 30.35%. On the other hand Vir Biotechnology, Inc. has an analysts' consensus of $20.22 which suggests that it could grow by 122.47%. Given that Vir Biotechnology, Inc. has higher upside potential than Harrow, Inc., analysts believe Vir Biotechnology, Inc. is more attractive than Harrow, Inc..

Harrow, Inc. has a beta of 0.073, which suggesting that the stock is 92.734% less volatile than S&P 500. In comparison Vir Biotechnology, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.258%.

Harrow, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow, Inc. pays -- of its earnings as a dividend. Vir Biotechnology, Inc. pays out -- of its earnings as a dividend.

Harrow, Inc. quarterly revenues are $71.6M, which are larger than Vir Biotechnology, Inc. quarterly revenues of $64.1M. Harrow, Inc.'s net income of $1M is higher than Vir Biotechnology, Inc.'s net income of -$42.9M. Notably, Harrow, Inc.'s price-to-earnings ratio is -- while Vir Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow, Inc. is 8.09x versus 18.37x for Vir Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings, Inc. has a net margin of 1.42% compared to Harrow, Inc.'s net margin of 0.84%. Harrow, Inc.'s return on equity of -8.95% beat Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2%.

Harrow, Inc. has a consensus price target of $70.63, signalling upside risk potential of 30.35%. On the other hand Xeris Biopharma Holdings, Inc. has an analysts' consensus of $11.14 which suggests that it could grow by 82.07%. Given that Xeris Biopharma Holdings, Inc. has higher upside potential than Harrow, Inc., analysts believe Xeris Biopharma Holdings, Inc. is more attractive than Harrow, Inc..

Harrow, Inc. has a beta of 0.073, which suggesting that the stock is 92.734% less volatile than S&P 500. In comparison Xeris Biopharma Holdings, Inc. has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.813%.

Harrow, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow, Inc. pays -- of its earnings as a dividend. Xeris Biopharma Holdings, Inc. pays out -- of its earnings as a dividend.

Harrow, Inc. quarterly revenues are $71.6M, which are smaller than Xeris Biopharma Holdings, Inc. quarterly revenues of $74.4M. Harrow, Inc.'s net income of $1M is higher than Xeris Biopharma Holdings, Inc.'s net income of $621K. Notably, Harrow, Inc.'s price-to-earnings ratio is -- while Xeris Biopharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow, Inc. is 8.09x versus 3.67x for Xeris Biopharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.